MarketInOut Stock Screener Log In | Sign Up

4basebio Plc

XETRA • Healthcare • Biotechnology • Quote as of 11/19/2026 17:35
4basebio Plc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeXETRA
Market Capitalization112.21 mln
Float4.67 mln
Earnings Date05/20/2027

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-1.01
Manipulation likely

Relative Strength

46 / 100
Slightly lagging

Debt / Equity

18.18
Extremely leveraged

Pre-Tax Margin

-2,378%
Severely loss-making

ROE

-178
Deeply negative

Business Description

Founded in 2008 and headquartered in Cambridge, UK, 4basebio PLC develops and produces synthetic DNA and RNA materials along with delivery systems for use in medicines and vaccines across Europe, the United States, and beyond. The company offers a range of specialized DNA products designed for applications such as gene therapy, mRNA production, genome editing, and DNA-based vaccines. It also owns a proprietary delivery platform called Hermes, which transports genetic and protein materials into cells and may serve as a more temperature-stable option compared to conventional fat-based delivery methods.

Key Fundamentals

EPS-1.33
ROE-178
RPS0.06
ROIC-158
ROA-57.81
Interest Cover-18.24
EBITDA, mln-18.96
EV / EBITDA-5.53
EV / EBIT-5.17
Revenue, mln0.90
EV / Revenue117

Quote Details

Last 5.85
Change 0 (0%)
Open 5.85
Volume 905
Turnover 5,294.25
Average Volume 417.71

Financial Ratios

Pre-Tax Profit Margin-2,378
Leverage Ratio21.33
Current Ratio5.98
Price / Book64.63
Debt / Equity18.18
Price / Sales106

Financial Strength

Altman Z-Score-1.15
Piotroski F-Score 4 / 9
Beneish M-Score-1.01

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0% 86 / 100   
1 Month -12.03% 10 / 100   
2 Months -2.5% 46 / 100   
6 Months 3.54% 67 / 100   
1 Year -45.83% 4 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog